Skip to main content
. 2024 Oct 9;635(8038):462–471. doi: 10.1038/s41586-024-07943-7

Extended Data Fig. 11. The randomized phase III POSEIDON clinical trial.

Extended Data Fig. 11

a, Clinicogenomic characteristics of mutation-evaluable patients with advanced nsNSCLC in the POSEIDON clinical trial. b, POSEIDON clinical trial schema. c, Mutation-evaluable population among patients with nsNSCLC. d, Venn diagram indicating overlap of somatic mutations in KRAS, STK11 and KEAP1 in the POSEIDON dataset.